A cellular model of amyloid precursor protein processing and amyloid-β peptide production

Journal of Neuroscience Methods

Volumn 223, Issue , 2014, Pages 114-122

  Macias, MiMi P ^a   Gonzales, Amanda M ^a   Siniard, Ashley L ^b   Walker, Aaron W ^a   Corneveaux, Jason J ^b   Huentelman, Matthew J ^b   Sabbagh, Marwan N ^a   Decourt, Boris ^a  

^a SUN HEALTH RESEARCH INSTITUTE   (United States)

^b TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

Author keywords

Alzheimer's; Amyloid beta; BE(2) M17; In vitro; Secretase; TNF

Indexed keywords

AMINO ACID; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; BETA SECRETASE; GAMMA SECRETASE; RETINOIC ACID; RNA;

ARTICLE; CANCER CELL CULTURE; CELL LINE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IN VITRO STUDY; MORPHOLOGY; NERVE DEGENERATION; NEUROBLASTOMA CELL; PRIORITY JOURNAL; PROTEIN PROCESSING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SEQUENCE; WESTERN BLOTTING;

ALZHEIMER'S; AMYLOID-BETA; BE(2)-M17; IN VITRO; SECRETASE; TNF;

AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ASPARTIC ACID ENDOPEPTIDASES; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KERATOLYTIC AGENTS; MODELS, BIOLOGICAL; NEUROBLASTOMA; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; TIME FACTORS; TRETINOIN;

EID: 84891362775     PISSN: 01650270     EISSN: 1872678X     Source Type: Journal    
DOI: 10.1016/j.jneumeth.2013.11.024     Document Type: Article

References (52)

1. Andrau D., Dumanchin-Njock C., Aryal E., Vizzavona J., Farzan M., Boisbrun M., et al. BACE1- and BACE2-expressing human cells. J Biol Chem 2003, 278(28):25859-25866.
2. Andres D., Keyser B.M., Petrali J., Benton B., Hubbard K.S., McNutt P.M., et al. Morphological and functional differentiation in BE(2)-M17 human neuroblastoma cells by treatment with trans-retinoic acid. BMC Neurosci 2013, 14:49.
3. Bien J., Jefferson T., Causevic M., Jumpertz T., Munter L., Multhaup G., et al. The metalloprotease meprin β generates amino terminal-truncated amyloid β peptide species. J Biol Chem 2012, 287(40):33304-33313.
4. Carter D.B., Dunn E., Pauley A.M., McKinley D.D., Fleck T.J., Ellerbrook B.R., et al. Changes in gamma-secretase activity and specificity caused by the introduction of consensus aspartyl protease active motif in presenilin 1. Mol Neurodegener 2008, 3:6.
5. Chow V.W., Mattson M.P., Wong P.C., Gleichmann M. An overview of APP processing enzymes and products. Neuromol Med 2010, 12(1):1-12.
6. Ciccarone V., Spengler B.A., Meyers M.B., Biedler J.L., Ross R.A. Phenotypic diversification in human neuroblastoma cells: expression of distinct neural crest lineages. Cancer Res 1989, 49(1):219-225.
7. Crestini A., Napolitano M., Piscopo P., Confaloni A., Bravo E. Changes in cholesterol metabolism are associated with PS1 and PS2 gene regulation in SK-N-BE. J Mol Neurosci 2006, 30:311-322.
8. De Strooper B., Vassar R., Golde T. The secretases: enzymes with therapeutic potential in Alzheimer disease. Nat Rev Neurol 2010, 6(2):99-107.
9. Decourt B., Gonzales A., Beach T.G., Malek-Ahmadi M., Walker A., Sue L., et al. BACE1 levels by APOE genotype in non-demented and Alzheimer's post-mortem brains. Curr Alzheimer Res 2013, 10(3):309-315.
10. Decourt B., Munnamalai V., Lee A.C., Sanchez L., Suter D.M. Cortactin colocalizes with filopodial actin and accumulates at IgCAM adhesion sites in Aplysia growth cones. J Neurosci Res 2009, 87(5):1057-1068.
11. 2+ homeostasis increases glutaminyl cyclase expression; connecting two early pathogenic events in Alzheimer's disease in vitro. PLoS ONE 2012, 7(9):e44674.
12. Dislich B., Lichtenthaler S.F. The membrane-bound aspartyl protease BACE1: molecular and functional properties in Alzheimer's disease and beyond. Front Physiol 2012, 3:8.
13. Donmez G., Outeiro T.F. SIRT1 and SIRT2: emerging targets in neurodegeneration. EMBO Mol Med 2013, 5(3):344-352.
14. Durkin J.T., Murthy S., Husten E.J., Trusko S.P., Savage M.J., Rotella D.P., et al. Rank-order of potencies for inhibition of the secretion of abeta40 and abeta42 suggests that both are generated by a single gamma-secretase. J Biol Chem 1999, 274(29):20499-20504.
15. Flammang B., Pardossi-Piquard R., Sevalle J., Debayle D., Dabert-Gay A.S., Thevenet A., et al. Evidence that the amyloid-β protein precursor intracellular domain, AICD, derives from β-secretase-generated C-terminal fragment. J Alzheimers Dis 2012, 30(1):145-153.
16. Flicek P., Amode M.R., Barrell D., Beal K., Brent S., Carvalho-Silva D., et al. Ensembl 2012. Nucleic Acids Res 2012, 40(Database issue):D84-D90.
17. Fuso A., Seminara L., Cavallaro R.A., D'Anselmi F., Scarpa S. S-adenosylmethionine/homocysteine cycle alterations modify DNA methylation status with consequent deregulation of PS1 and BACE and beta-amyloid production. Mol Cell Neurosci 2005, 28(1):195-204.
18. Glass C.K., Saijo K., Winner B., Marchetto M.C., Gage F.H. Mechanisms underlying inflammation in neurodegeneration. Cell 2010, 140(6):918-934.
19. Gouras G.K., Xu H., Jovanovic J.N., Buxbaum J.D., Wang R., Greengard P., et al. Generation and regulation of beta-amyloid peptide variants by neurons. J Neurochem 1998, 71(5):1920-1925.
20. Hampel H., Shen Y., Walsh D.M., Aisen P., Shaw L.M., Zetterberg H., et al. Biological markers of amyloid beta-related mechanisms in Alzheimer's disease. Exp Neurol 2010, 223(2):334-346.
21. He P., Zhong Z., Lindholm K., Berning L., Lee W., Lemere C., et al. Deletion of tumor necrosis factor death receptor inhibits amyloid beta generation and prevents learning and memory deficits in Alzheimer's mice. J Cell Biol 2007, 178(5):829-841.
22. Hoe H.S., Cooper M.J., Burns M.P., Lewis P.A., van der Brug M., Chakraborty G., et al. The metalloprotease inhibitor TIMP-3 regulates amyloid precursor protein and apolipoprotein E receptor proteolysis. J Neurosci 2007, 27(40):10895-10905.
23. Iqbal K., Liu F., Gong C.X., Grundke-Iqbal I. Tau in Alzheimer disease and related tauopathies. Curr Alzheimer Res 2010, 7:656-664.
24. Iwatsubo T., Odaka A., Suzuki N., Mizusawa H., Nukina N., Ihara Y. Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). Neuron 1994, 13(1):45-53.
25. Jarrett J.T., Berger E.P., Lansbury P.T. The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry 1993, 32(18):4693-4697.
26. Kandalepas P.C., Vassar R. Identification and biology of β-secretase. J Neurochem 2012, 120(Suppl. 1):55-61.
27. Korner M., Tarantino N., Pleskoff O., Lee L.M., Debre P. Activation of nuclear factor kappa B in human neuroblastoma cell lines. J Neurochem 1994, 62(5):1716-1726.
28. Kuhn P.-H., Wang H., Dislich B., Colombo A., Zeitschel U., Ellwart J.W., et al. ADAM10 is the physiologically relevant, constitutive α-secretase of the amyloid precursor protein in primary neurons. EMBO 2010, 29(17):3020-3032.
29. Lahiri D.K., Ge Y.W. Role of the APP promoter in Alzheimer's disease: cell type-specific expression of the beta-amyloid precursor protein. Ann N Y Acad Sci 2004, 1030:310-316.
30. Lahiri D.K., Nall C. Promoter activity of the gene encoding the beta-amyloid precursor protein is up-regulated by growth factors, phorbol ester, retinoic acid and interleukin-1. Brain Res Mol Brain Res 1995, 32(2):233-240.
31. Langmead B., Salzberg S.L. Fast gapped-read alignment with Bowtie 2. Nat Methods 2012, 9(4):357-359.
32. Lee H.P., Casadesus G., Zhu X., Lee H.G., Perry G., Smith M.A., et al. All-trans retinoic acid as a novel therapeutic strategy for Alzheimer's disease. Expert Rev Neurother 2009, 9(11):1615-1621.
33. Ly P.T., Wu Y., Zou H., Wang R., Zhou W., Kinoshita A., et al. Inhibition of GSK3beta-mediated BACE1 expression reduces Alzheimer-associated phenotypes. J Clin Invest 2013, 123(1):224-235.
34. Masters C.L., Selkoe D.J. Biochemistry of amyloid β-protein and amyloid deposits in Alzheimer disease. Cold Spring Harb Perspect Med 2012, 2(6):a006262.
35. Mucke L. Alzheimer's disease. Nature 2009, 461:895-897. [October 15].
36. Murayama K.S., Kametani F., Araki W. Extracellular release of BACE1 holoproteins from human neuronal cells. Biochem Biophys Res Commun 2005, 338:800-807.
37. Oppenheimer O., Cheung N.K., Gerald W.L. The RET oncogene is a critical component of transcriptional programs associated with retinoic acid-induced differentiation in neuroblastoma. Mol Cancer Ther 2007, 6(4):1300-1309.
38. Pluta R., Furmaga-Jablonska W., Maciejewski R., Ulamek-Koziol M., Jablonski M. Brain ischemia activates beta- and gamma-secretase cleavage of amyloid precursor protein: significance in sporadic Alzheimer's disease. Mol Neurobiol 2013, 47(1):425-434.
39. Rajadas J., Sun W., Li H., Inayathullah M., Cereghetti D., Tan A., et al. Enhanced Aβ(1-40) production in endothelial cells stimulated with fibrillar Aβ(1-42). PLoS ONE 2013, 8(3):e58194.
40. Sato N., Okochi M., Shinohara M., Thinakaran G., Takeda S., Fukumori A., et al. Differential regulation of amyloid precursor protein/presenilin 1 interaction during Aβ40/42 [corrected] production detected using fusion constructs. PLoS ONE 2012, 7(11):e48551.
41. Selkoe D.J. Alzheimer's disease: genotypes, phenotypes, and treatments. Science 1997, 275(5300):630-631.
42. Seubert P., Vigo-Pelfrey C., Esch F., Lee M., Dovey H., Davis D., et al. Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids. Nature 1992, 359(6393):325-327.
43. Sevalle J., Amoyel A., Robert P., Fournie-Zaluski M.C., Roques B., Checler F. Aminopeptidase A contributes to the N-terminal truncation of amyloid beta-peptide. J Neurochem 2009, 109:248-256.
44. Sutinen E.M., Pirttila T., Anderson G., Salminen A., Ojala J.O. Pro-inflammatory interleukin-18 increases Alzheimer's disease-associated amyloid-beta production in human neuron-like cells. J Neuroinflamm 2012, 9:199.
45. Thiele C.J. Neuroblastoma cell lines. Human cell culture 1998, vol. 1:21-53. Kluwer Academic Publishers, Lancaster.
46. Trapnell C., Roberts A., Goff L., Pertea G., Kim D., Kelley D.R., et al. Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. Nat Protoc 2012, 7(3):562-578.
47. Trapnell C., Schatz M.C. Optimizing data intensive GPGPU Computations for DNA sequence alignment. Parallel Comput 2009, 35(8):429-440.
48. Valenti M.T., Bolognin S., Zanatta C., Donatelli L., Innamorati G., Pampanin M., et al. Increased glutaminyl cyclase expression in peripheral blood of Alzheimer's disease patients. J Alzheimers Dis 2013, 34(1):263-271.
49. Vassar R., Kovacs D.M., Yan R., Wong P.C. The B-secretase enzyme BACE in health and Alzheimer's disease: regulation, cell biology, function, and therapeutic potential. J Neurosci 2009, 29(41):12787-12794.
50. Weggen S., Eriksen J.L., Das P., Sagi S.A., Wang R., Pietrzik C.U., et al. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 2001, 414(6860):212-216.
51. Yiannopoulou K.G., Papageorgiou S.G. Current and future treatments for Alzheimer's disease. Ther Adv Neurol Disord 2013, 6(1):19-33.
52. Zhang H., Ma Q., Zhang Y.-w., Xu H. Proteolytic processing of Alzheimer's B-amyloid precursor protein. J Neurochem 2012, 120(Suppl. 1):9-21.